Treatment of multiple sclerosis with laquinimod

Abstract of the Disclosure The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laqui...

Full description

Saved in:
Bibliographic Details
Main Authors KOFLER, DINA, TARCIC, NORA, BAR-ZOHAR, DAN
Format Patent
LanguageEnglish
Published 01.09.2016
Subjects
AGRICULTURE
ANIMAL HUSBANDRY
BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES
FISHING
FORESTRY
HUMAN NECESSITIES
HUNTING
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PEST REPELLANTS OR ATTRACTANTS
PLANT GROWTH REGULATORS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF
TRAPPING
Online AccessGet full text

Cover

More Information
Summary:Abstract of the Disclosure The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. The subject invention also provides for pharmaceutical oral unit dosage forms of 0.6 mg laquinimod for use in reducing the relapse rate and/or for use in reducing the accumulation of physical disability in a relapsing remitting multiple sclerosis human patient.
Bibliography:Application Number: AU20160216586